• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Genovis

19.94 SEK

-0.30 %

1,631 following

GENO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.30 %
-1.04 %
+19.54 %
-6.16 %
+0.71 %
-23.75 %
-59.80 %
-56.70 %
-27.17 %

Genovis delivers biotechnology tools and technology platforms to the life sciences and pharmaceutical industries. The company develops enzyme and inhibitor technologies that facilitate, or are integral parts of, a wide range of processes from basic research to pharmaceutical manufacturing and diagnostics. The company operates on a global scale, with customers primarily in North America, Europe and East Asia. Genovis was founded in 1999 and is headquartered in Kävlinge.

Read more
Market cap
1.35B SEK
Turnover
433.82K SEK
Revenue
128.95M
EBIT %
16.5 %
P/E
55.39
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Forum discussions
Time for the AGM. The management remains the same, and the remuneration system is being refined, linking it specifically to the development phase (dividends are not the target). Authorization is requested for a share issue of 6.6 million shares (which would mean a 10% dilution as...
4/17/2026, 8:38 PM
by LeBaron
6
I see this as a much more positive step than the previous news, moving towards participating in drug manufacturing technology rather than selling enzymes for others to research. So, two different lines are being built: Research tools and Therapeutics licensing. This new move has ...
3/26/2026, 6:22 AM
by LeBaron
6
MFN – 24 Jul 25 Genovis Expands License Agreement to Access Proprietary Enzyme Tech... Genovis AB, a leading provider of innovative enzyme technologies, today announced an expansion of its license agreement with Thermo Fisher Scientific to gain access to proprietary enzyme technology...
7/24/2025, 6:32 AM
by sillinkutoja
6
Inderes Genovis and Single Cell Discoveries Enter Strategic Partnership for... Genovis AB, a leading provider of innovative enzyme technologies, today announces a strategic partnership with Single Cell Discoveries to broaden the application of the SEQURNA® Thermostable... Genovis...
3/19/2026, 7:47 AM
by Simba
5
A bit of a monologue here. Oh well, at least I won’t start arguing with myself. The annual report provides more detail on the reflections I shared above. I hope to get answers from the AGM to at least these: how much of the 2025 growth came from ADC? (core revenue +17%, currency-...
4/27/2026, 2:25 PM
by LeBaron
4
Good that business is good. It seems to me that Genovis is a premier enzyme supplier whose products have unique properties and thus pricing power. I’m holding this with a small weighting, waiting for better times.
3/25/2026, 1:36 PM
by Clark kent
3
Nordnet Nordnet Tee säästämisestä osakkeisiin & rahastoihin hauskempaa. Sijoittaminen osakkeisiin, rahastoihin ja ETF:iin ilman tarpeettomia kuluja. Tervetuloa Suomen tyytyväisimpien sijoittajien joukkoon! Avaa tili jo tänään! Genovis and Plasmidsaurus Introduce SEQguard™ Dino Preserve...
3/31/2026, 3:14 PM
by LeBaron
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
23/7
2026

Interim report Q2'26

10/11
2026

Interim report Q3'26

Regulatory press release6/1/2026, 4:00 PM

Genovis förvärvar KPL och utökar sin enzymplattform med en unik portfölj av precisionsproteaser för proteinanalys

Genovis
Regulatory press release6/1/2026, 4:00 PM

Genovis Acquires KPL — Expanding Its Enzyme Platform with a Proprietary Portfolio of Precision Proteases for Protein Analysis

Genovis
Regulatory press release5/18/2026, 5:47 PM

Kommuniké från Årsstämman i Genovis AB (publ) den 18 maj 2026

Genovis

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/18/2026, 5:47 PM

Communiqué from Genovis AB (publ) Annual General Meeting May 18, 2026

Genovis
Regulatory press release5/12/2026, 11:56 AM

Genovis meddelar förändring i finanschefspositionen

Genovis
Regulatory press release5/12/2026, 11:56 AM

Genovis Announces Change in Chief Financial Officer Position

Genovis
Press release5/11/2026, 6:30 AM

Genovis och MGI Tech stärker samarbetet inom RNA-sekvensering

Genovis
Press release5/11/2026, 6:30 AM

Genovis and MGI Tech Strengthen Collaboration to Advance RNA Sequencing Solutions

Genovis
Regulatory press release4/28/2026, 6:00 AM

Genovis AB Interim Report January-March 2026

Genovis
Regulatory press release4/28/2026, 6:00 AM

Genovis AB Delårsrapport januari-mars 2026

Genovis
Regulatory press release4/23/2026, 6:00 AM

Genovis AB publicerar Årsredovisning 2025

Genovis
Regulatory press release4/23/2026, 6:00 AM

Genovis AB publishes Annual Report 2025

Genovis
Regulatory press release4/15/2026, 10:15 AM

KALLELSE TILL ÅRSSTÄMMA I GENOVIS AB (PUBL)

Genovis
Regulatory press release4/15/2026, 10:15 AM

NOTICE OF ANNUAL GENERAL MEETING OF GENOVIS AB (PUBL)

Genovis
Press release3/31/2026, 7:00 AM

Genovis och Plasmidsaurus lanserar SEQguard™ Dino Preserve — möjliggör RNA-frakt i rumstemperatur för nästa generations sekvensering (NGS)

Genovis
Press release3/31/2026, 7:00 AM

Genovis and Plasmidsaurus Introduce SEQguard™ Dino Preserve — Enabling Ambient-Temperature RNA Shipping for Next-Generation Sequencing

Genovis
Regulatory press release3/25/2026, 7:30 AM

Genovis ingår icke-exklusivt licensavtal för EndoS2-enzymteknologi för utveckling och kommersialisering av antikroppskonjugat (ADC)

Genovis
Regulatory press release3/25/2026, 7:30 AM

Genovis Enters Non-Exclusive License Agreement for EndoS2 Enzyme Technology for Antibody-Drug Conjugate (ADC) Development and Commercialization

Genovis
Press release3/19/2026, 7:30 AM

Genovis och Single Cell Discoveries ingår strategiskt partnerskap för storskaliga analyser av genuttryck

Genovis
Press release3/19/2026, 7:30 AM

Genovis and Single Cell Discoveries Enter Strategic Partnership for Large-Scale Transcriptomics Analyses

Genovis